Home > Expertise > Healthcare > Patient advocacy

Patient advocacy

Patient advocacy Agency Consulting firm Experts Specialists Consultancy

The Alcimed Healthcare team has been exploring the topics of patient advocacy and patient centricity for the past 20+ years, helping its clients understand how patient advocates or patient advocacy groups work, what they can do and how they can contribute to the research and development, the market access, or to improving patient pathway of novel pharmaceutical products and diagnostics.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.


    They trust us

    Logo_carre_Air_Liquide_HC
    Logo_carre_Bayer
    Logo_carre_Biomerieux
    Logo_carre_Boehringer_Ingelheim
    Logo_carre_J&J
    Logo_carre_Merck&co
    Logo_carre_Moderna
    Logo_carre_Novartis
    Logo_carre_Sanofi

    The challenges related to patient advocacy

    Up until recently, patient advocates were considered secondary players in the healthcare system. Fortunately, attitudes are shifting, and patients are becoming more and more empowered. At Alcimed, we believe that this trend is here to stay and will further complexify an already complex and heterogeneous landscape. The patient voice carries more and more weight:

    • Patients know it, regulators such as the FDA and the EMA know it and are giving more importance to patient input and may be on the verge of requesting it as part of the submission dossier.
    • More and more payers are asking for patient feedback.
    • Pharmaceutical and medical technology companies are making concrete steps to involve the patient throughout the years it takes to bring innovation to the market.

    This trend is opening new horizons with new challenges and opportunities. It can sometimes feel like trying to find a needle in a haystack to identify the right group to partner with on the right topic. And once you have found your needle, a host of strategic and operational issues arise:

    Given the increasingly complex landscape, defining and finding the right partners is far from obvious: not all stakeholders can or want to work with pharmaceutical or medical device companies. Their skills, knowledge, experience and interests vary widely. Not everyone understands the intricacies of conducting clinical trials for instance. Not everyone has connections in the public health or political spheres.

    Who are the right partners for this asset or this therapeutic area? How to identify them?

    What creates value for both parties? The diversity of individuals and organizations in patient advocacy means that there is no one-size-fits-all. Patient advocates are very diverse in nature ranging from government agencies to non-for-profit and for-profit organizations. Once you have found the right partner, it is important to work on developing long term value-creating relationships for both parties.

    What do advocates expect from healthcare players? How to create true long-term win-win partnerships with advocates?

    By experience, patient feedback is always interesting and can serve the improvement of a clinical study or any action that is targeting patients. However, it is not always possible to implement. On this point, the devil is often in the details and there are essentially three categories of reasons: scientific, technical or organizational.

    What feedback on what topic at what frequency and at what stage of the development? And how to implement (or sometimes not) this feedback?

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.


      How we support you in your projects related to patient advocacy

      This patient advocacy trend is opening new horizons with new challenges and opportunities. It can sometimes feel like trying to find a needle in a haystack to identify the right group to partner with on the right topic. And once you have found your needle, a host of strategic and operational issues arise: what creates value for both parties? Who are the right partners for this asset or this therapeutic area? What feedback on what topic at what frequency and at what stage of the development? How to implement (or sometimes not) this feedback?

      Our team can help you move forward and make the right decisions on these topics. Over the past decade, we have helped small biotechnology start-ups, large pharmaceutical and medical technology companies explore, adapt, and lead the change in the patient advocacy landscape.

      We can help you:

      • Understand trends related to advocacy in your specific indication or therapeutic area,
      • Identify the relevant stakeholders to partner with,
      • Explore topics and partnership modalities,
      • Truly embed the patient voice inside your organization.

      Examples of recent projects carried out for our clients in patient advocacy

      • Creation of the patient advocacy strategy of a pharmaceutical company

        Our client, a Top 10 biopharmaceutical company realized that its ambition of patient centricity had translated into cultural change within the company but did not yet consistently materialized into day-to-day operations.

        Our team worked with internal stakeholders in all functions involved in the product development and commercialization, from early R&D to life cycle management to identify gaps and opportunities.

        We then created a process through a series of cross-functional workshops, aiming at defining how should patient centricity take place in all operations daily. Prior to validate and implement this new process, our team vetted it with patient advocates.

      • Operational implementation and operationalization of a patient advocacy strategy

        We helped a leading pharmaceutical player in rolling out its patient advocacy strategy and in embedding all activities designed in an implementation roadmap into the company governance, with the sponsorship of the executive leadership team.

        Our team created training materials, standard operating procedures, and moderated onboarding sessions for each function to train internal stakeholders. Together with our client we evaluated which assets could first benefit these activities and identified the right patient advocacy groups for the job to be done on each asset.

        In parallel, we created tools to facilitate engagements with PAGs, report the outcome of the interaction and created a KPI dashboard to monitor progress and communicate internally – and externally! Throughout this whole project, we provided project management until the launch and the post-launch were successful.

      • Identification and prioritization of relevant patient associations to partner with across 4 therapeutic areas in North America, Europe and APAC

        Our healthcare team helped the Patient Advocacy team of a mid-sized pharmaceutical company in conducting a landscape assessment of patient advocacy groups in several indications in different therapeutic areas.

        Once the mapping was completed, we identified key stakes for each therapeutic area, conducted a gap analysis to prioritize which therapeutic area to focus on and explored unmet needs and activities to initiate or reinforce with relevant partners in each therapeutic area.

        Our investigation led us to making recommendations to the Corporate Affairs team on short- and long-term activities in the 3 regions in-scope (North America, Europe and APAC).

      • Competitive benchmark for patient advocacy in the fight against AMR

        One of our clients, a global pharmaceutical player, wanted to further develop its patient advocacy strategy, in order to have better tools to fight against antimicrobial resistance (AMR).

        They had a knowledge gap on what other players in the AMR space were doing in terms of patient advocacy and wanted to fill this gap to develop and potentially improve their patient advocacy strategy. To do so, Alcimed screened competitors’ strategies across several regions and analyzed the similarities and differences as well as the most impactful actions.

        Followig our investigation and analysis, our team made recommendations to our client on the best path forward to lead this space.

      You have a project?

        Tell us about your uncharted territory

        You have a project and want to discuss it with our explorers, write us!

        One of our explorers will contact you shortly.


        To go further

        Founded in 1993, Alcimed is an innovation and new business consulting firm, specializing in innovation driven sectors: life sciences (healthcare, biotech, agrifood), energy, environment, mobility, chemicals, materials, cosmetics, aeronautics, space and defence.

        Our purpose? Helping both private and public decision-makers explore and develop their uncharted territories: new technologies, new offers, new geographies, possible futures, and new ways to innovate.

        Located across eight offices around the world (France, Europe, Singapore and the United States), our team is made up of 220 highly-qualified, multicultural and passionate explorers, with a blended science/technology and business culture.

        Our dream? To build a team of 1,000 explorers, to design tomorrow’s world hand in hand with our clients.

        Patient advocacy is any activity which ultimately benefits the patient. This definition encompasses a wide variety of activities, organizations, and individuals.

        To name just a few:

        • Government agencies like the Center for Disease Control and Prevention (CDC), the European Medicine Agency (EMA), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), etc.
        • Not-for-profit Patient Advocacy Groups (PAGs), also known as Patient Organizations or Patient Associations in different parts of the world, are organizations that lobby or advocate for one or several diseases and / or causes (g. Alzheimer’s Association, European Multiple Sclerosis Platform, Black Health Matters,…).
        • Individual Patient Advocate, whose profile and knowledge of healthcare or science may vary. In this category we find caregivers, family members, as well as for-profit advocates who act like case managers or social workers.
        • For-profit PAG: in recent years, there has been an increase in the number of groups staffed by professionals who help patients navigate the healthcare system and reimbursement landscape for a fee, usually covered by the patients and/or their benefactors.

        Patient advocacy is not a new concept. It emerged in the 1950s in the United States in the context of cancer research. In those early days of cancer treatment, patients and their families questioned the ethics of certain clinical research practices.

        In the 1970s, patient advocacy gained momentum in the USA as the Patient Rights movement grew. One of the major advocacy organization at the time, the National Welfare Rights Organization successfully managed to influence the Joint Commission to create hospital accreditation standards, as well as the American Hospital Association’s Patient Bill of Rights of 1972.

        The utilization of patient advocates by individual patients then gained further momentum in the early 2000s in the USA due to a number of drivers: the professionalization of this activity, the democratization of the Internet and social media, and past successes of patient advocacy and Patient Rights.

        Today, it is not possible anymore to say exactly how many patient advocacy groups exist in the world, as it is probably in the thousands. The sheer number and variety of PAGs is a testimony to the success of this approach. They cover everything from ultra-rare diseases to entire therapeutic areas and span from Facebook groups with a few dozen patients, caregivers and family members focused on patient education and awareness to national and even international foundations able to raise money, fund research, facilitate clinical trial recruitment, improve access and health equity, suggest new clinical guidelines recommendations, influence payers, lobby for new laws, etc.